Sugi Predict

Sugi Predict / Compounds / N-Methylpiperidine

N-Methylpiperidine

N-Methylpiperidine

SCHEMBL996509

CN1CCCCC1.O=C(Cl)Cl

nearest known ligand 0.59

Full drug profile on Sugi Atlas →

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 1/20 0.42
▸ CYP1A2 P05177 2/20 0.42
▸ TDP1 Q9NUW8 1/20 0.42
▸ ALDH1A1 P00352 3/20 0.39
▸ HTT P42858 1/20 0.39
▸ HRH3 Q9Y5N1 1/20 0.38
▸ KMT2A Q03164 2/20 0.37
▸ MAPT P10636 2/20 0.37
▸ POLB P06746 1/20 0.37
▸ L3MBTL1 Q9Y468 1/20 0.36
▸ TSHR P16473 1/20 0.35
▸ GFER P55789 1/20 0.35
▸ SIGMAR1 Q99720 1/20 0.35
▸ CA12 O43570 1/20 0.34
▸ CA2 P00918 1/20 0.34
▸ CA9 Q16790 1/20 0.34
▸ MAPK1 P28482 1/20 0.34
▸ SMN1; SMN2 Q16637 1/20 0.34
▸ HSD11B1 P28845 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
N-Methylpiperidine SCHEMBL11210549 0.85 CYP1A2 (0.50) LMNACYP1A2TDP1ALDH1A1HTT
N-Methylpiperidine SCHEMBL3849400 0.82 ALDH1A1 (0.47) LMNACYP1A2TDP1ALDH1A1HTT
N-Methylpiperidine SCHEMBL3145445 0.82 CYP1A2 (0.48) LMNACYP1A2TDP1ALDH1A1HTT
N-Methylpiperidine SCHEMBL11256632 0.81 — —
N-Methylpiperidine SCHEMBL6603929 0.81 — —
N-Methylpiperidine SCHEMBL6660565 0.80 HRH3 (0.37) LMNACYP1A2TDP1ALDH1A1HTT
SCHEMBL12316976 0.80 HRH3 (0.37) LMNACYP1A2TDP1ALDH1A1HTT
SCHEMBL414741 0.80 HRH3 (0.37) LMNACYP1A2TDP1ALDH1A1HTT
N-Methylpiperidine SCHEMBL1920 0.80 — —
SCHEMBL21960469 0.80 HRH3 (0.37) LMNACYP1A2TDP1ALDH1A1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9062037-B2 Tazarotene derivatives STIEFEL LABORATORIES, INC. (US) 2015-06-23 — — US disclosed
US-20140357672-A1 TAZAROTENE DERIVATIVES STIEFEL LABORATORIES, INC. 2014-12-04 — — US disclosed
US-20140357669-A1 TAZAROTENE DERIVATIVES STIEFEL LABORATORIES, INC. 2014-12-04 — — US disclosed
EP-2453746-A1 TAZAROTENE DERIVATIVES Stiefel Laboratories, Inc. (US) 2012-05-23 — — EP disclosed
US-20120115909-A1 TAZAROTENE DERIVATIVES STIEFEL LABORATORIES, INC. 2012-05-10 — — US disclosed
WO-2011009023-A1 TAZAROTENE DERIVATIVES STIEFEL LABORATORIES, INC. (US) 2011-01-20 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140357672-A1 TAZAROTENE DERIVATIVES RXRA, RARA, RXRB LMNA 2137/4885CYP1A2 834/4885TDP1 1220/4885
US-20140357669-A1 TAZAROTENE DERIVATIVES RXRA, RARA, RXRB LMNA 2137/4885CYP1A2 834/4885TDP1 1220/4885
US-20120115909-A1 TAZAROTENE DERIVATIVES RXRA, RARA, RXRB LMNA 2137/4885CYP1A2 834/4885TDP1 1220/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.